Systolic blood pressure > 180 mmHg, or diastolic blood pressure > 110 mmHg at screening.

Known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months before screening

Serum sodium < 135 mmol/L at the Screening Visit (values obtained within 4 weeks prior to screening or at the Screening Visit).

Diabetes mellitus:

1. T1DM at the screening visit
2. Uncontrolled T2DM at screening: HbA1C > 10.5% (> 91 mmol/mol)

New York Heart Association functional HF class IV at screening

Any use of mineralocorticoid receptor antagonists (such as spironolactone, eplerenone, or finerenone), aldosterone synthase inhibitors, potassium-sparing diuretics (such as triamterene or amiloride), or potassium binders (such as sodium zirconium cyclosilicate, patiromer, or sodium polystyrene sulfonate) within 4 weeks prior to screening

Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, or hospitalisation for worsening HF within previous 3 months prior to randomisation.

Known severe hepatic impairment, defined as Child-Pugh Class C, based on records that confirm documented medical history.

Documented history of adrenal insufficiency.

Any dialysis (including for acute kidney injury) within 3 months prior to the screening

Any acute kidney injury within 3 months prior to the screening visit.

Prohibited concomitant medications